Brasco Group Invest 8 Million Euro in Charles Real Estate Joint Venture Deal
22.2.2023 20:34:00 EET | Business Wire | Press release
The Brasco B.V. conglomerate is establishing a joint venture with the real estate company Charles Real Estate.
The Dutch company is thus consolidating its position in the German residential and commercial real estate market.
The Brasco Group continues on its investment tour: with its strategic investment in the joint venture with Charles Real Estate, the Dutch conglomerate is further diversifying its portfolio.
As a first step, the Brasco Group is investing EUR 8 million in the joint venture, and in the course of 2023 is planning to invest a further EUR 30 million.
Charles Real Estate, based in Berlin, has a portfolio of 550 units in Germany with a total lettable space of more than 33,000 square metres. The company's portfolio also includes a property currently under construction with a gross floor area of 16,000 square metres.
Industry insiders regard the investment as proof of the German real estate market's stability. As the coronavirus pandemic appears to have been largely overcome and the energy crisis has been less severe than initially feared, analysts see further growth potential in the German real estate market.
This is already the second investment by the Dutch group to attract attention this year: at the beginning of February, the company announced that it was investing in Mood's Clinic, a well-known manufacturer of medical cannabis.
The Brasco Group is a Dutch conglomerate and parent company of the Brasco group of companies. The Group specialises in trade and logistics, real estate development, financial services – in particular private equity – and the distribution of textiles. The main task of the parent company is to define the strategic orientation of the individual spheres of business and to promote their growth as well as the use of synergies through investment and communication.
The Dutch conglomerate relies on innovative trade concepts to remain competitive in the global and fast-moving circulation of goods and services.
The Group's core competence in the real estate sector is the purchase and management of existing high-end properties in sought-after locations within the Federal Republic of Germany.
The Brasco Group's finance division is responsible for managing and controlling the finances of subsidiaries, suppliers, partners, shareholders and investors. Only employees of the Brasco group of companies are authorised to manage finances, which ensures finances are managed securely.
The investment division of the conglomerate plays a central role in the acquisition of majority stakes: in recent decades, the company has advised on half of all global buyouts with a sales volume of more than $500 million. In addition to buy-out funds, the Brasco Group advises on other types of fund, including hedge funds, real estate funds, private equity funds and infrastructure funds. The Dutch company also advises pension fund, sovereign wealth fund and foundation managers.
More than 1,000 investment experts are associated with the company, and they accompany the investment cycle from the contract negotiation stage to planning the withdrawal.
The Brasco Group intends to float itself on the stock market at the end of 2024.
The Managing Director of the Brasco Group is Rafy Ahmed.
Rafy Ahmed is known to the public from the TV show "Lion's Den". Ahmed founded the fashion brand "Morotai" in 2017 which specialises in sportswear. In 2018, he was awarded the Founder's Prize of the State of Baden-Württemberg. In addition to his work as CEO, he is a lecturer at the International School of Management (ISM) in Stuttgart. As a successful young entrepreneur, he shows students how to start their career. The ISM Stuttgart intends to make the course he teaches an integral part of the "Global Brand & Fashion Management" degree course.
|
Language: |
English |
|
Company: |
Brasco Group |
|
Rivium Boulevard 301 beganegrond en 1e etage |
|
|
2909LK Capelle aan den IJsse |
|
|
Netherlands |
|
|
Internet: |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005788/en/
Contact information
Name: Rafy Ahmed
Tel: +905337840707
Email: info@brascogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom